A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Exclusion Criteria

• •Subjects must not have a diagnosis of any other inflammatory Arthritis
• •Subjects must not have greater than 3 Arthroplasties due to Rheumatoid Arthritis and/or Steinbrocker IV Functional Capacity
• •Subjects must not have a secondary non-inflammatory type of Arthritis that would interfere with study evaluation
• •Subjects must not be diagnosed with Fibromyalgia with sufficient symptoms requiring treatment
• •Subjects must not have a history of Infected Joint Prosthesis
• •Subjects must not have discontinued biological therapy for their Rheumatoid Arthritis due to Severe Hypersensitivity Reaction or Anaphylactic Reaction
• •Subjects must not have received more than 2 anti- Tumor Necrosis Factor (TNF) agents prior to enrollment
• •Subjects must not have received treatment with Abatacept and/or Rituximab or have received any experimental or approved B cell therapeutic agent
• •Subjects must not have a history of chronic alcohol or drug abuse
• •Subjects must not have known hypersensitivity to any components of the investigational medicinal product
• •Subjects must not have a history of chronic infections, recent serious or life-threatening infection within 6 months or any current sign or symptom that may indicate an infection
• •Subjects must not have a history of a Blood Dyscrasias
• •Subjects with known Tuberculosis (TB) Disease, high risk of acquiring TB or latent TB infection
• •Subjects must not be at high risk of infection
• •Subjects must not have a history of Lymphoproliferative Disorder including Lymphoma signs and symptoms suggestive of Lymphoproliferative Disease
• •Subjects must not have concurrent acute or chronic Viral Hepatitis B or C
• •Subjects must not have known Human Immunodeficiency Virus (HIV) infection
• •Subject must not have concurrent Malignancy or history of Malignancy
• •Subjects must not have a current or recent history of severe, progressive, and/or uncontrolled Renal, Hepatic, Hematological, Gastrointestinal, Endocrine, Pulmonary, Cardiac, Neurological or Cerebral Disease
• •Subjects must not have Class III or IV Congestive Heart Failure
• •Subjects must not have history of, or suspected Demyelinating Disease of the Central Nervous System
• •Subjects must not have a history of adverse reaction to Polyethylene Glycol (PEG)
• •Subjects must not have significant laboratory abnormalities which in the investigators judgment would make the subject unsuitable for inclusion
• •Subjects must not have a known history or clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, Nontuberculous Mycobacteria, Blastomyces or Aspergillus
• •Subject must not have a known history of or be currently diagnosed with Systemic Lupus Erythematosus